147 related articles for article (PubMed ID: 36595876)
1. Network meta-analysis and cost-effectiveness analysis of infliximab, cyclosporine and tacrolimus for ulcerative colitis.
Wang X; Li Q; Sun S; Liang X; Li H; Huang J; Zhao T; Hu J; Liu J; Hu Z; Duan Y; He J
Medicine (Baltimore); 2022 Dec; 101(51):e31850. PubMed ID: 36595876
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis.
Komaki Y; Komaki F; Micic D; Yamada A; Suzuki Y; Sakuraba A
J Gastroenterol Hepatol; 2017 Jun; 32(6):1143-1151. PubMed ID: 27957761
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; López-Del Val A
Eur J Hosp Pharm; 2020 Nov; 27(6):355-360. PubMed ID: 33097619
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis.
Jia X; Guo R; Hu Z; Liu J; Liu J; Li B; Yang Q; He J
Medicine (Baltimore); 2020 Oct; 99(44):e22894. PubMed ID: 33126341
[TBL] [Abstract][Full Text] [Related]
7. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
[TBL] [Abstract][Full Text] [Related]
9. Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial.
Alam MF; Longo M; Cohen D; Groves S; Alrubaiy L; Hutchings HA; Watkins A; Sebastain S; Williams JG
BMC Health Serv Res; 2023 Mar; 23(1):226. PubMed ID: 36890533
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.
Punekar YS; Hawkins N
Eur J Health Econ; 2010 Feb; 11(1):67-76. PubMed ID: 19844750
[TBL] [Abstract][Full Text] [Related]
11. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT).
Williams JG; Alam MF; Alrubaiy L; Clement C; Cohen D; Grey M; Hilton M; Hutchings HA; Longo M; Morgan JM; Rapport FL; Seagrove AC; Watkins A
Health Technol Assess; 2016 Jun; 20(44):1-320. PubMed ID: 27329657
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands.
Chaudhary MA; Fan T
Biol Ther; 2013; 3(1):45-60. PubMed ID: 24392304
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive therapy for progressive idiopathic membranous nephropathy: a cost-effectiveness analysis in China.
Xu W; Zhang Z; Li D; Dai W; Pan C; Guo M; Zhao Y; Cui X
BMC Health Serv Res; 2023 Apr; 23(1):361. PubMed ID: 37046255
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
[TBL] [Abstract][Full Text] [Related]
15. Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis.
Liu YJ; Fan H; Zhen WW; Yu X; Chen JT; Wang CD
Medicine (Baltimore); 2018 Aug; 97(32):e11440. PubMed ID: 30095612
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis.
Park KT; Perez F; Tsai R; Honkanen A; Bass D; Garber A
J Pediatr Gastroenterol Nutr; 2011 Nov; 53(5):489-96. PubMed ID: 21694634
[TBL] [Abstract][Full Text] [Related]
17. A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.
Tappenden P; Ren S; Archer R; Harvey R; James MM; Basarir H; Stevens J; Lobo A; Hoque S
Pharmacoeconomics; 2016 Oct; 34(10):1023-38. PubMed ID: 27125898
[TBL] [Abstract][Full Text] [Related]
18. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis.
Yamagami H; Nishida Y; Nagami Y; Hosomi S; Yukawa T; Otani K; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
Rom J Intern Med; 2017 Sep; 55(3):151-157. PubMed ID: 28222041
[TBL] [Abstract][Full Text] [Related]
19. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
20. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
Tsai HH; Punekar YS; Morris J; Fortun P
Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
